For years, rare renal cell carcinomas (RCCs), such as papillary RCC, have been understudied because their incidences are too low to support clinical trials. Kyrollis Attalla, MD, believes Mount Sinai could overcome that challenge through a cutting-edge approach: laboratory-grown tumor organoids that mimic the parent tumor in the body.